Author:
Ma Muya,Xu Lingling,Cui Wenhua,Huang Yan,Chi Gang
Abstract
AbstractAcute myeloid leukemia (AML) is one of the most common hematological malignancy that has a high recurrence rate. FIBP was reported to be highly expressed in multiple tumor types. However, its expression and role in acute myeloid leukemia remains largely unknown. The aim of this study was to clarify the role and value of FIBP in the diagnosis and prognosis, and to analyze its correlation with immune infiltration in acute myeloid leukemia by The Cancer Genome Atlas (TCGA) dataset. FIBP was highly expressed in AML samples compared to normal samples. The differentially expressed genes were identified between high and low expression of FIBP. The high FIBP expression group had poorer overall survival. FIBP was closely correlated with CD4, IL-10 and IL-2. The enrichment analysis indicated DEGs were mainly related to leukocyte migration, leukocyte cell–cell adhesion, myeloid leukocyte differentiation, endothelial cell proliferation and T cell tolerance induction. FIBP expression has significant correlation with infiltrating levels of various immune cells. FIBP could be a potential targeted therapy and prognostic biomarker associated with immune infiltrates for AML.
Funder
Scientific and Technologial Innovation Programs of Higher Education Institutions in Shanxi
Fund Program for the Scientific Activities of Selected Returned Overseas Professionals in Shanxi Province
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Endocrine and Autonomic Systems,Endocrinology,Oncology,Endocrinology, Diabetes and Metabolism
Reference32 articles.
1. Piotr O, Anna K, Jakub W, Julia T, Monika L, Zawitkowska JZ. Molecular-targeted therapy of Pediatric Acute myeloid leukemia. Molecules. 2022;27(12):3911.
2. Huang XB, Zhou D, Ye XJ, Jin J. A novel ferroptosis-related gene signature can predict prognosis and influence immune microenvironment in acute myeloid leukemia. Bosn J Basic Med Sci. 2022;22(4):608–28.
3. Su YZ, Wang CB, Zhou Y, Sun NT. Effects of changes in serum endostatin and fibroblast growth factor 19 on the chemotherapeutic sensitivity in acute myeloid leukemia patients. Genet Mol Res. 2015;14(2):5181–7.
4. Martner A, Thorén FB, Aurelius J, Hellstrand K. Immunotherapeutic strategies for relapse control in acute myeloid leukemia. Blood Rev. 2013;27(5):209–16.
5. Kolpakova E, Wiedlocha A, Stenmark H, Klingenberg O, Falnes PO, Olsnes S. Cloning of an intracellular protein that binds selectively to mitogenic acidic fibroblast growth factor. Biochem J. 1998;336:213–22.